 1960-1968. 
"A stout girl, looking well, came to the hospital on account of general weakness; she could scarely walk or move about, she spoke slowly and had slight strabismus. The house physician was inclined to regard the case as one of hysteria . . . every movement of her limbs and speech was performed so slowly and deliberately that the case seemed rather one of lethargy from want of will than an actual paralysis. She spoke most indistinctly, swallowed with great difficulty, and was quite unable to cough. The limbs were, however, not paralysed, as she was able to get out of her bed. It was shortly afterwards seen that her respiration was becoming affected, the difficulty of which rapidly increased, and in a few hours she died. The medulla oblongata was very carefully examined, and no disease found." ' This account by Samuel Wilks in 1877 of a 22-year-old girl with bulbar paralysis, who died of ventilatory failure, is widely regarded as one of the earliest case reports of the disease later known as myasthenia gravis. We use the term ventilatory failure as defined by Sykes, McNicholl and Campbell.2 This state is characterised by a raised arterial carbon dioxide (pCO2) and results either from a reduction in total ventilation, or from a failure to compensate for imparied carbon dioxide elimination by increasing ventilation. This most feared of all complications of myasthenia gravis may occur suddenly or insidiously and is often difficult to detect particularly during the early stages of the disease. The 8 % mortality rate during the first year of severe myasthenia prior to the institution of the anticholinesterase drugs in 1934 was due mainly to this occurrence.3 Improved respiratory care has been a major factor in the steady reduction in mortality.
Ashworth and Hunter4 when reporting their findings in ten myasthenic patients with ventilatory failure who were admitted to the Respiratory Care Unit at Manchester Royal Infirmary during the period 1960-1968 found a 70% mortality rate.
The purpose of the present study is to examine the precipitating factors and outcome of ventilatory failure in a further thirty-one myasthenic patients admitted to the same hospital during the following decade. An unusual case of chronic alveolar hypoventilation is discussed in detail.
Patients and results
Between 1969 and 1978, 31 out of 154 patients attending the Neurological Service with myasthenia gravis developed ventilatory failure. In all of these, voluntary respiratory effort either ceased or was so ineffective as to require assisted ventilation. The majority of our patients experienced sudden ventilatory failure and therefore required immediate resuscitation. Blood gas values (all abnormal) were obtained in only ten of the 31 cases and only four had vital capacity measurements prior to assisted ventilation.
The group consisted of 17 men whose mean age at onset of myasthenia was 54 years (range 27 to 76 years) and 14 women with a mean age of 38 years (range 12 to 64 years). The interval between the onset of myasthenic symptoms and ventilatory failure varies from 5 days to 27 years. The length of this interval bore no relationship to the age of the patient. We have divided the patients into four categories depending on the presumed precipitating cause of their breathing difficulty: myasthenic crisis, cholinergic crisis, steroid induced crisis, and brittle crisis (see fig 1) . D During the decade under study 11 of the 31 patients died (four patients were not available for follow up). Death occurred on average 9-8 months (range 2 days to 9 years) after the onset of ventilatory failure and in those cases, the average total duration of myasthenic symptoms prior to the onset of failure was 4 years (range 3 months to 15 years). The causes of death are outlined in table 1 . Seven patients died from disease The cholinergic crisis with respiratory muscle weakness due to depolarisation block is usually accompanied by gastrointestinal symptoms and an excess of oropharyngeal secretions. The most valuable clinical muscarinic feature is said to be the size of the pupil which should not be allowed to contract to less than 2 mm.15 In this series only one case had meiosis at the time of ventilatory failure. We found, as did Voisin,16 that the peripheral nicotinic signs of fasciculation and muscular cramps were a rare feature during the state of crisis. Osserman and Genkins5 stress that edrophonium should be avoided wherever the possibility of a cholinergic crisis is suspected. A test dose of edrophonium or neostigmine may actually precipitate apnoea as occurred with four patients in our series.
The dramatic decrease in muscle strength with corticotrophin as a result of increase in neuromuscular blockade is a feature unique to myasthenia gravis.17 It has been suggested that this unwanted action of corticotrophin is due to the acceleration of hydrolysis of acetylcholine by an increase in cholinesterase activity at the neuromuscular junction.18 However, recent experimental evidence in rabbits with experimental autoimmune myasthenia gravis given corticotrophin suggests the mechanism may be due to enhancement of the immunological response .19 In humans this decrease in strength usually occurs within the first five days of steroid treatment.'7 Ventilatory failure in our corticotrophintreated group took place on average at 5 8 days (range 3-10 days).
In our series the best outcome was seen in the younger patients with a hyperplastic thymus where the precipitating cause for ventilatory failure was a cholinergic crisis. The worst result occurred in the older patients with a short history of myasthenia and an atrophic gland. The cause of ventilatory failure in the latter group was usually a myasthenic crisis and the clinical picture was frequently compounded by unrelated pathology. Voisin 
